SYM FINANCIAL Corp Buys Shares of 888 Becton, Dickinson and Company (NYSE:BDX)

SYM FINANCIAL Corp purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 888 shares of the medical instruments supplier’s stock, valued at approximately $201,000.

Several other institutional investors have also modified their holdings of BDX. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company during the third quarter worth $33,000. Tompkins Financial Corp raised its holdings in shares of Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company during the 3rd quarter worth about $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the transaction, the executive vice president now directly owns 6,141 shares in the company, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,844 shares of company stock worth $2,210,716 over the last ninety days. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler upped their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 0.3 %

NYSE:BDX opened at $247.63 on Monday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $250.91. The firm has a market capitalization of $71.82 billion, a price-to-earnings ratio of 41.69, a price-to-earnings-growth ratio of 1.79 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock’s 50 day moving average price is $230.53 and its two-hundred day moving average price is $233.83.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.42 earnings per share. Equities research analysts expect that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.